美國居民不適用 XM 服務。

Dental implants maker Straumann sales boosted by strong Asia Pacific



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Straumann shares slip on slowing US dental implant demand</title></head><body>

Shares down 10.5% at 1046 GMT

Organic growth slows in N.America and EMEA

CEO says high interest rates hit US patient traffic

Q1 organic sales growth 15.1%, with 82% jump in APAC

Recasts with share reaction, CEO comments in paragraphs 2-4

By Mateusz Dobrzyniewski and Marleen Kaesebier

April 30 (Reuters) -Shares in Swiss dental implants maker Straumann STMN.S fell more than 10% on Tuesday, as slower U.S. sales growth took the shine off an 82% organic rise in the Asia Pacific region.

There has been some slowdown in terms of patients seeking treatment in the U.S. since last year, Straumann CEO Guillaume Daniellot said in a results call.

"It was always related to a spending capacity being impacted by higher interest rate," Daniellot said, noting many U.S. households use credit to pay for treatment.

Because of this, high interest rates have much bigger impact on North America than Europe, Daniellot added.

Straumann said its organic revenue rose 15.1% to 643.8 million Swiss francs ($706.5 million) in the first quarter, with strong demand for its premium implants in Asia Pacific.

"The report was great, it was a beat, but it was entirely a beat because of Asia Pacific, because of China," Stifel analyst Daniel Jelovcan told Reuters.

Growth slowed in Straumann's two biggest regions, Europe, Middle East and Africa (EMEA) and North America, which reported organic sales rises of 5.2% and 3.7%, respectively.

Jelovcan said the softer U.S. market likely took many by a surprise, as consumer sentiment has been improving.

Straumann reaffirmed its 2024 organic revenue growth forecast in the high single-digit percentage range. That includes 15-20% growth in China from the second half of the year, Daniellot said.

The company is among the winners from China's volume-based procurement (VBP) programme for healthcare products, which has brought down selling prices but boosted demand.

Straumann flagged a larger patient flow in China due to the VBP and a low comparison base, but did not provide detailed results for the region.

($1 = 0.9113 Swiss francs)



Reporting by Mateusz Dobrzyniewski and Marleen Käsebier in Gdansk; Editing by Milla Nissi and Alexander Smith

</body></html>

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明